Q3 2024 EPS Estimates for DexCom, Inc. (NASDAQ:DXCM) Decreased by Leerink Partnrs

DexCom, Inc. (NASDAQ:DXCM) – Leerink Partnrs dropped their Q3 2024 earnings estimates for DexCom in a research report issued to clients and investors on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings of $0.44 per share for the quarter, down from their prior estimate of $0.45. The consensus estimate for DexCom’s current full-year earnings is $1.69 per share. Leerink Partnrs also issued estimates for DexCom’s Q4 2024 earnings at $0.47 EPS, Q1 2025 earnings at $0.29 EPS, Q2 2025 earnings at $0.52 EPS, Q3 2025 earnings at $0.58 EPS, Q4 2025 earnings at $0.66 EPS, FY2025 earnings at $2.03 EPS, FY2026 earnings at $2.49 EPS, FY2027 earnings at $2.90 EPS and FY2028 earnings at $3.38 EPS.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company’s quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.34 EPS.

A number of other analysts also recently weighed in on the stock. Stifel Nicolaus upped their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Wells Fargo & Company cut their target price on DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, October 12th. UBS Group dropped their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, Baird R W cut DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Seven analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $110.73.

DexCom Trading Up 4.2 %

DXCM opened at $69.90 on Thursday. The stock has a market capitalization of $27.80 billion, a price-to-earnings ratio of 45.10, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a 50-day simple moving average of $69.95 and a 200 day simple moving average of $101.15.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the sale, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,824 shares of company stock worth $126,390. 0.30% of the stock is currently owned by company insiders.

Institutional Trading of DexCom

A number of large investors have recently bought and sold shares of DXCM. Crewe Advisors LLC bought a new stake in shares of DexCom during the 1st quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of DexCom during the 2nd quarter worth approximately $25,000. Riverview Trust Co acquired a new stake in shares of DexCom during the 1st quarter worth approximately $32,000. Sachetta LLC increased its stake in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares in the last quarter. Finally, Sound Income Strategies LLC lifted its position in shares of DexCom by 41.7% during the 1st quarter. Sound Income Strategies LLC now owns 340 shares of the medical device company’s stock valued at $47,000 after acquiring an additional 100 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.